EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria

Rie Tatsugawa, Kengo Kidokoro, Tsukasa Iwakura, Akira Hirano, Eriko Kajimoto, Masanobu Takasu, Masafumi Wada, Hiroshi Kitao, Yoshihisa Wada, Georgina Gyarmati, Seiji Kishi, Hajime Nagasu und 4 weitere

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfaf232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Rie Tatsugawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Albuminuria, Glomerular Filtration Rate, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Japan Society for the Promotion of Science, Kawasaki Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic kidney disease (DKD) is a major cause of chronic kidney disease, with glomerular hyperfiltration contributing to its progression. Esaxerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), reduces albuminuria, but its precise mechanism remains unclear. Mineralocorticoid receptor (MR) activation is implicated in tubuloglomerular feedback (TGF) dysregulation, and we hypothesized that MR inhibition attenuates albuminuria by mitigating glomerular hyperfiltration.

Methods

To investigate the effects of esaxerenone, we used aldosterone-induced MR activation rats and type 2 diabetic (db/db) mice. In vivo multiphoton imaging was performed to assess the single-nephron glomerular filtration rate (SNGFR) and arteriolar diameters. Macula densa (MD) cells were used to examine MR activation’s impact on TGF.

Results

In aldosterone-infused rats, MR activation induced glomerular hyperfiltration via afferent arteriolar dilation, which was attenuated by esaxerenone. In db/db mice, esaxerenone reduced SNGFR and urinary albumin excretion while increasing urinary adenosine levels, effects reversed by A1aR blockade. In MD cells, MR activation increased nitric oxide (NO) production and reduced Na+-K+-2Cl− cotransporter membrane expression, both of which were mitigated by MRA or neuronal nitric oxide synthase inhibition.

Conclusion

These findings suggest that esaxerenone restores TGF function via adenosine signalling, attenuating glomerular hyperfiltration and reducing albuminuria. This study provides novel insights into the albuminuria-lowering effects of MR blockade in DKD and supports the therapeutic potential of esaxerenone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsAlbuminuriaGlomerular Filtration RatePyrrolesSulfonesDiabetic NephropathiesKidney GlomerulusDiabetes Mellitus, Type 2AnimalsRatsMiceMaleMice, Inbred C57BLAldosteroneRats, Sprague-Dawley

Stichwörter der Autor:innen

adenosinediabetic kidney diseaseglomerular haemodynamicsnon-steroidal mineralocorticoid receptor antagonisttubuloglomerular feedback

Substanzen

Mineralocorticoid Receptor AntagonistsesaxerenonePyrrolesSulfonesAldosterone

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.
  • Department of Physiology and Neuroscience and Department of Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA, USA.
  • Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Kawasaki Medical School, Kawasaki Geriatric Medical Center, Kurashiki, Okayama, Japan.

Förderung

  • NIDDK NIH HHS
  • Japan Society for the Promotion of Science
  • Kawasaki Medical School
  • Daiichi Sankyo
  • CIHR
  • Heart and Stroke Richard Lewar Centre of Excellence
  • Heart and Stroke Foundation
  • Kidney Foundation of Canada

Zitieren

APA

Tatsugawa, R., Kidokoro, K., Iwakura, T., Hirano, A., Kajimoto, E., Takasu, M., Wada, M., Kitao, H., Wada, Y., Gyarmati, G., Kishi, S., Nagasu, H., Cherney, D. Z. I., Peti-Peterdi, J., Sasaki, T., & Kashihara, N. (2026). The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf232

Vancouver

Tatsugawa R, Kidokoro K, Iwakura T, Hirano A, Kajimoto E, Takasu M, et al. The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf232

BibTeX
@article{Tatsugawa2026,
  author = {Tatsugawa, Rie and Kidokoro, Kengo and Iwakura, Tsukasa and Hirano, Akira and Kajimoto, Eriko and Takasu, Masanobu and Wada, Masafumi and Kitao, Hiroshi and Wada, Yoshihisa and Gyarmati, Georgina and Kishi, Seiji and Nagasu, Hajime and Cherney, David Z I and Peti-Peterdi, Janos and Sasaki, Tamaki and Kashihara, Naoki},
  title = {The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfaf232}
}
Kostenlos starten →